RapidCaP, a novel gem model for metastatic prostate cancer analysis and therapy, reveals Myc as a driver of Pten-mutant metastasis

Cancer Discovery

Volumn 4, Issue 3, 2014, Pages 319-333

  Cho, Hyejin ^a   Herzka, Tali ^a   Zheng, Wu ^a   Qi, Jun ^d   Wilkinson, John E ^e   Bradner, James E ^d   Robinson, Brian D ^b   Castillo Martin, Mireia ^c   Cordon Cardo, Carlos ^c   Trotman, Lloyd C ^a  

^a Howard Hughes Medical Institute Cold Spring Harbor Laboratory Cold Spring Harbor   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(+) JQ1 COMPOUND; (+)-JQ1 COMPOUND; AZEPINE DERIVATIVE; MYC PROTEIN; PHARMACOLOGY; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P53; PROTEIN S6; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NKX3.1; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; C57BL MOUSE; CASTRATION; CONTROLLED STUDY; DNA EXTRACTION; DRUG ADMINISTRATION; EXPERIMENTAL NEOPLASM; FLUORESCENCE ACTIVATED CELL SORTING; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION REGULATION; GENE MUTATION; GENE VECTOR; GENETIC ENGINEERING; GENETICS; HEK293 CELL LINE; HUMAN; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; METASTASIS; MOUSE; NONHUMAN; ONCOGENE MYC; PATHOLOGY; PROSTATE CANCER; PROSTATE TUMOR; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAPIDCAP MODEL; RETROVIRUS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; TRANSGENIC MOUSE; VIRAL GENE DELIVERY SYSTEM; WESTERN BLOTTING;

ADMINISTRATION AND DOSAGE; ANIMALS; AZEPINES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC VECTORS; GENETICS; HEK293 CELLS; HUMANS; MALE; METABOLISM; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASM METASTASIS; NEOPLASMS, EXPERIMENTAL; PATHOLOGY; PHARMACOLOGY; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MYC; PTEN PHOSPHOHYDROLASE; RETROVIRIDAE; TRIAZOLES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84895823244     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-13-0346     Document Type: Article

References (44)

1. Huggins C, Stevens RC, Hodges CV. Studies on prostatic cancer: II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 1941;43:209-223.
2. Chen Y, Scher HI. Prostate cancer in 2011: hitting old targets better and identifying new targets. Nat Rev Clin Oncol 2012;9:70-2.
3. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver B S, et al. Integrative genomic profi ling of human prostate cancer. Cancer Cell 2010;18:11-22.
4. Baca SC, Garraway LA. The genomic landscape of prostate cancer. Front Endocrinol 2012;3:69.
5. Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat JP, et al. Exome sequencing identifi es recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet 2012;44:685-689.
6. Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY, et al. The genomic complexity of primary human prostate cancer. Nature 2011;470:214-220.
7. Irshad S, Abate-Shen C. Modeling prostate cancer in mice: something old, something new, something premalignant, something metastatic. Cancer Metastasis Rev 2013;32:109-122.
8. Podsypanina K, Ellenson LH, Nemes A, Gu J, Tamura M, Yamada KM, et al. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci U S A 1999;96:1563-1568.
9. Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP. Pten is essential for embryonic development and tumour suppression. Nat Genet 1998;19:348-355.
10. Di Cristofano A, De Acetis M, Koff A, Cordon-Cardo C, Pandolfi P P. Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat Genet 2001;27:222-224.
11. Trotman LC, Niki M, Dot an ZA, Koutcher JA, Di Cristofano A, Xiao A, et al. Pten dose dictates cancer progression in the prostate. PLoS Biol 2003;1:E59.
12. Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J, et al. Prostate-specifi c deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 2003;4:209-221.
13. King JC, Xu J, Wongvipat J, Hieronymus H, Carver BS, Leung DH, et al. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet 2009;41:524-526.
14. Ellwood-Yen K, Graeber TG, Wongvipat J, Iruela-Arispe ML, Zhang J, Matusik R, et al. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 2003;4:223-238.
15. Trotman LC, Alimonti A, Scaglioni PP, Koutcher JA, Cordon-Cardo C, Pandolfi PP. Identifi cation of a tumour suppressor network opposing nuclear Akt function. Nature 2006;441:523-527.
16. Heyer J, Kwong LN, Lowe SW, Chin L. Non-germline genetically engineered mouse models for translational cancer research. Nat Rev Cancer 2010;10:470-480.
17. Singh M, Ferrara N. Modeling and predicting clinical effi cacy for drugs targeting the tumor milieu. Nat Biotechnol 2012;30:648-657.
18. Singh M, Murriel CL, Johnson L. Genetically engineered mouse models: closing the gap between preclinical data and trial outcomes. Cancer Res 2012;72:2695-2700.
19. Ittmann M, Huang J, Radaelli E, Martin P, Signoretti S, Sullivan R, et al. Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee. Cancer Res 2013;73:2718-2736.
20. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science 2013;339:1546-1558.
21. Chen M, Pratt CP, Zeeman ME, Schultz N, Taylor BS, O'Neill A, et al. Identifi cation of PHLPP1 as a tumor suppressor reveals the role of feedback activation in PTEN-mutant prostate cancer progression. Cancer Cell 2011;20:173-186.
22. Chen Z, Trotman LC, Shaffer D, Lin HK, Dot an ZA, Niki M, et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 2005;436:725-730.
23. Ding Z, Wu CJ, Chu GC, Xiao Y, Ho D, Zhang J, et al. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature 2011;470:269-273.
24. Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chan-darlapaty S, et al. Reciprocal feedback regulation of PI3K and andro-gen receptor signaling in PTEN-defi cient prostate cancer. Cancer Cell 2011;19:575-586.
25. Iwata T, Schultz D, Hicks J, Hubbard GK, Mutton LN, Lotan TL, et al. MYC overexpression induces prostatic intraepithelial neoplasia and loss of Nkx3.1 in mouse luminal epithelial cells. PLoS ONE 2010;5:e9427.
26. Harrington LS, Findlay GM, Lamb RF. Restraining PI3K: mTOR signalling goes back to the membrane. Trends Biochem Sci 2005;30: 35-42.
27. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006;66:1500-1508.
28. Vasudevan KM, Barbie DA, Davies MA, Rabinovsky R, McNear CJ, Kim JJ, et al. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell 2009;16:21-32.
29. Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, et al. RNAi screen identifi es Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011; 478: 524-528.
30. Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, e t al. Selective inhibition of BET bromodomains. Nature 2010; 468: 1067-1073.
31. Shi J, Whyte WA, Zepeda-Mendoza CJ, Milazzo JP, Shen C, Roe JS, et al. Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated Myc regulation. Genes Dev 2013;27:2648-2662.
32. Puzio-Kuter AM, Castillo-Martin M, Kinkade CW, Wang X, Shen TH, Matos T, et al. Inactivation of p53 and Pten promotes invasive bladder cancer. Genes Dev 2009;23:675-680.
33. DuPage M, Dooley AL, Jacks T. Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat Protoc 2009;4:1064-1072.
34. Alimonti A, Nardella C, Chen Z, Clohessy JG, Carracedo A, Trotman LC, et al. A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis. J Clin Invest 2010;120:681-693.
35. Kim JS, Lee C, Bonifant CL, Ressom H, Waldman T. Activation of p53-dependent growth suppression in human cells by mutations in PTEN or PIK3CA. Mol Cell Biol 2007;27:662-677.
36. Nardella C, Clohessy JG, Alimonti A, Pandolfi PP. Pro-senescence therapy for cancer treatment. Nat Rev Cancer 2011;11:503-511.
37. Liu W, Laitinen S, Khan S, Vihinen M, Kowalski J, Yu G, et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med 2009;15:559-565.
38. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012;487:239-243.
39. Conacci-Sorrell M, Ngouenet C, Eisenman RN. Myc-nick: a cytoplas-mic cleavage product of Myc that promotes alpha-tubulin acetylation and cell differentiation. Cell 2010;142:480-493.
40. Kim J, Roh M, Doubinskaia I, Algarroba GN, Eltoum IE, Abdulkadir SA. A mouse model of heterogeneous, c-MYC-initiated prostate cancer with loss of Pten and p53. Oncogene 2012;31:322-332.
41. Clegg NJ, Couto SS, Wongvipat J, Hieronymus H, Carver BS, Taylor BS, et al. MYC cooperates with AKT in prostate tumorigenesis and alters sensitivity to mTOR inhibitors. PLoS ONE 2011;6:e17449.
42. Wang J, Kobayashi T, Floc'H N, Kinkade CW, Aytes A, Dankort D, et al. B-Raf activation cooperates with PTEN loss to drive c-Myc expression in advanced prostate cancer. Cancer Res 2012;72:4765-4776.
43. Jonkers J, Meuwissen R, Van der Gulden H, Peterse H, Van der Valk M, Berns A. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet 2001; 29: 418-425.
44. Marino S, Vooijs M, van Der Gulden H, Jonkers J, Berns A. Induction of medulloblastomas in p53-null mutant mice by somatic inactiva-tion of Rb in the external granular layer cells of the cerebellum. Genes Dev 2000;14:994-1004.